Literature DB >> 27531367

Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.

Robert W Cross1,2, Chad E Mire1,2, Luis M Branco3, Joan B Geisbert1,2, Megan M Rowland3, Megan L Heinrich3, Augustine Goba4,5, Mambu Momoh4,5,6, Donald S Grant4,5, Mohamed Fullah4,5, Sheik Humarr Khan4,5, James E Robinson7, Thomas W Geisbert1,2, Robert F Garry3,8.   

Abstract

Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27531367      PMCID： PMC5032844          DOI： 10.1016/j.antiviral.2016.08.012

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  15 in total

1.  [The first imported case of Lassa fever in Japan].

Authors:  Y Hirabayashi; S Oka; H Goto; K Shimada; T Kurata; S P Fisher-Hoch; J B McCormick
Journal:  Nihon Rinsho       Date:  1989-01

2.  Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization.

Authors:  P B Jahrling; J D Frame; J B Rhoderick; M H Monson
Journal:  Trans R Soc Trop Med Hyg       Date:  1985       Impact factor: 2.184

3.  Exchange transfusion of a patient with fulminant Lassa fever.

Authors:  D Cummins; D Bennett; S J Machin
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

4.  Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease.

Authors:  E Leifer; D J Gocke; H Bourne
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

5.  Lassa fever: the challenges of curtailing a deadly disease.

Authors:  Titus Ibekwe
Journal:  Pan Afr Med J       Date:  2012-03-23

6.  Lassa fever in post-conflict sierra leone.

Authors:  Jeffrey G Shaffer; Donald S Grant; John S Schieffelin; Matt L Boisen; Augustine Goba; Jessica N Hartnett; Danielle C Levy; Rachael E Yenni; Lina M Moses; Mohammed Fullah; Mambo Momoh; Mbalu Fonnie; Richard Fonnie; Lansana Kanneh; Veronica J Koroma; Kandeh Kargbo; Darin Ottomassathien; Ivana J Muncy; Abigail B Jones; Megan M Illick; Peter C Kulakosky; Allyson M Haislip; Christopher M Bishop; Deborah H Elliot; Bethany L Brown; Hu Zhu; Kathryn M Hastie; Kristian G Andersen; Stephen K Gire; Shervin Tabrizi; Ridhi Tariyal; Mathew Stremlau; Alex Matschiner; Darryl B Sampey; Jennifer S Spence; Robert W Cross; Joan B Geisbert; Onikepe A Folarin; Christian T Happi; Kelly R Pitts; F Jon Geske; Thomas W Geisbert; Erica Ollmann Saphire; James E Robinson; Russell B Wilson; Pardis C Sabeti; Lee A Henderson; S Humarr Khan; Daniel G Bausch; Luis M Branco; Robert F Garry
Journal:  PLoS Negl Trop Dis       Date:  2014-03-20

7.  Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.

Authors:  James E Robinson; Kathryn M Hastie; Robert W Cross; Rachael E Yenni; Deborah H Elliott; Julie A Rouelle; Chandrika B Kannadka; Ashley A Smira; Courtney E Garry; Benjamin T Bradley; Haini Yu; Jeffrey G Shaffer; Matt L Boisen; Jessica N Hartnett; Michelle A Zandonatti; Megan M Rowland; Megan L Heinrich; Luis Martínez-Sobrido; Benson Cheng; Juan C de la Torre; Kristian G Andersen; Augustine Goba; Mambu Momoh; Mohamed Fullah; Michael Gbakie; Lansana Kanneh; Veronica J Koroma; Richard Fonnie; Simbirie C Jalloh; Brima Kargbo; Mohamed A Vandi; Momoh Gbetuwa; Odia Ikponmwosa; Danny A Asogun; Peter O Okokhere; Onikepe A Follarin; John S Schieffelin; Kelly R Pitts; Joan B Geisbert; Peter C Kulakoski; Russell B Wilson; Christian T Happi; Pardis C Sabeti; Sahr M Gevao; S Humarr Khan; Donald S Grant; Thomas W Geisbert; Erica Ollmann Saphire; Luis M Branco; Robert F Garry
Journal:  Nat Commun       Date:  2016-05-10       Impact factor: 14.919

Review 8.  Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever.

Authors:  Daniel G Bausch; Christiane M Hadi; Sheik Humarr Khan; Juan J L Lertora
Journal:  Clin Infect Dis       Date:  2010-11-08       Impact factor: 9.079

9.  Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants.

Authors:  Asunción Mejías; Octavio Ramilo
Journal:  Biologics       Date:  2008-09

10.  Imported Lassa fever, Pennsylvania, USA, 2010.

Authors:  Valerianna Amorosa; Adam MacNeil; Ryan McConnell; Ami Patel; Katherine E Dillon; Keith Hamilton; Bobbie Rae Erickson; Shelley Campbell; Barbara Knust; Deborah Cannon; David Miller; Craig Manning; Pierre E Rollin; Stuart T Nichol
Journal:  Emerg Infect Dis       Date:  2010-10       Impact factor: 6.883
View more
  30 in total

1.  Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of Single-Cycle Replicating Lassa Virus Replicon Particles.

Authors:  Markus H Kainulainen; Jessica R Spengler; Stephen R Welch; JoAnn D Coleman-McCray; Jessica R Harmon; Florine E M Scholte; Cynthia S Goldsmith; Stuart T Nichol; César G Albariño; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2019-09-13       Impact factor: 5.226

2.  Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity.

Authors:  Helena Müller; Sarah Katharina Fehling; Jens Dorna; Richard A Urbanowicz; Lisa Oestereich; Yvonne Krebs; Larissa Kolesnikova; Martin Schauflinger; Verena Krähling; N'Faly Magassouba; Elisabeth Fichet-Calvet; Jonathan K Ball; Andreas Kaufmann; Stefan Bauer; Stephan Becker; Veronika von Messling; Thomas Strecker
Journal:  NPJ Vaccines       Date:  2020-08-04       Impact factor: 7.344

3.  Human antibody pieces together the puzzle of the trimeric Lassa virus surface antigen.

Authors:  Antra Zeltina; Thomas A Bowden
Journal:  Nat Struct Mol Biol       Date:  2017-07-06       Impact factor: 15.369

4.  Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus.

Authors:  Marko Zivcec; Lisa I W Guerrero; César G Albariño; Éric Bergeron; Stuart T Nichol; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2017-08-24       Impact factor: 5.970

5.  Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.

Authors:  Chad E Mire; Robert W Cross; Joan B Geisbert; Viktoriya Borisevich; Krystle N Agans; Daniel J Deer; Megan L Heinrich; Megan M Rowland; Augustine Goba; Mambu Momoh; Mathew L Boisen; Donald S Grant; Mohamed Fullah; Sheik Humarr Khan; Karla A Fenton; James E Robinson; Luis M Branco; Robert F Garry; Thomas W Geisbert
Journal:  Nat Med       Date:  2017-09-04       Impact factor: 53.440

6.  Structural basis for antibody-mediated neutralization of Lassa virus.

Authors:  Kathryn M Hastie; Michelle A Zandonatti; Lara M Kleinfelter; Megan L Heinrich; Megan M Rowland; Kartik Chandran; Luis M Branco; James E Robinson; Robert F Garry; Erica Ollmann Saphire
Journal:  Science       Date:  2017-06-02       Impact factor: 47.728

7.  Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.

Authors:  Kathryn M Hastie; Robert W Cross; Stephanie S Harkins; Michelle A Zandonatti; Anatoliy P Koval; Megan L Heinrich; Megan M Rowland; James E Robinson; Thomas W Geisbert; Robert F Garry; Luis M Branco; Erica Ollmann Saphire
Journal:  Cell       Date:  2019-08-08       Impact factor: 66.850

8.  Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak.

Authors:  Matthew L Boisen; Eghosa Uyigue; John Aiyepada; Katherine J Siddle; Lisa Oestereich; Diana K S Nelson; Duane J Bush; Megan M Rowland; Megan L Heinrich; Philomena Eromon; Adeyemi T Kayode; Ikponmwosa Odia; Donatus I Adomeh; Ekene B Muoebonam; Patience Akhilomen; Grace Okonofua; Blessing Osiemi; Omigie Omoregie; Michael Airende; Jacqueline Agbukor; Solomon Ehikhametalor; Chris Okafi Aire; Sophie Duraffour; Meike Pahlmann; Wiebke Böhm; Kayla G Barnes; Samar Mehta; Mambu Momoh; John Demby Sandi; Augustine Goba; Onikepe A Folarin; Ephraim Ogbaini-Emovan; Danny A Asogun; Ekaete A Tobin; George O Akpede; Sylvanus A Okogbenin; Peter O Okokhere; Donald S Grant; John S Schieffelin; Pardis C Sabeti; Stephan Günther; Christian T Happi; Luis M Branco; Robert F Garry
Journal:  Sci Rep       Date:  2020-05-26       Impact factor: 4.379

Review 9.  Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development.

Authors:  Francis Ifedayo Ibukun
Journal:  Viruses       Date:  2020-03-31       Impact factor: 5.048

Review 10.  Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development.

Authors:  Hoai J Hallam; Steven Hallam; Sergio E Rodriguez; Alan D T Barrett; David W C Beasley; Arlene Chua; Thomas G Ksiazek; Gregg N Milligan; Vaseeharan Sathiyamoorthy; Lisa M Reece
Journal:  NPJ Vaccines       Date:  2018-03-20       Impact factor: 7.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.